Serine Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.) Patents (Class 424/94.64)
  • Patent number: 11413192
    Abstract: The present invention is directed to a flowable hemostatic paste comprising a crosslinked carboxymethyl cellulose and at least one non-toxic dispersant. More specifically the present invention relates to a hemostatic paste containing citric acid cross-linked CMC, which is suspended or dispersed as a powder in a mixture of a first non-toxic glycerol-containing hygroscopic dispersant and a second non-toxic alcohol functionalized dispersant comprising propylene glycol or 1,3-butanediol.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: August 16, 2022
    Assignees: Guangzhou Bioseal Co., Ltd., Johnson & Johnson China Ltd., Ethicon Inc.
    Inventors: Dengmin Feng, Ling Teng, Yanhui Zhang, Guojun Ni, Yufu Li, Xiang Wan
  • Patent number: 11400180
    Abstract: The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: August 2, 2022
    Assignee: Ethicon, Inc.
    Inventors: Randolph W. Hubbell, James Eckhardt, Jerome Riebman, Yufu Li, Michael Elser
  • Patent number: 11332470
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 17, 2022
    Assignee: X4 Pharmaceuticals, Inc.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • Patent number: 11286303
    Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: March 29, 2022
    Assignee: Phaim Pharma Ltd
    Inventor: Tihamer Orban
  • Patent number: 11278480
    Abstract: The present invention relates to an antimicrobial composition at the pH of the skin. Particularly, it relates to an antimicrobial composition comprising water soluble vinyl polymer, a carboxylic acid having pKa greater than 4.5; and an anionic surfactant, wherein the composition has pH in the range 4.5 to 6.5. The compositions provides synergistic antimicrobial effect in relatively shorter contact time. The invention further relates to a method of disinfecting a surface using the composition.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: March 22, 2022
    Assignee: CONOPCO, INC.
    Inventors: Sameer Keshav Barne, Maya Treesa Saji
  • Patent number: 11213574
    Abstract: Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 4, 2022
    Assignee: Thrombolytic Science, LLC
    Inventor: Victor Gurewich
  • Patent number: 11208645
    Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 28, 2021
    Assignee: DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
  • Patent number: 11179311
    Abstract: The present invention relates to the novel trypsin ZT isoforms. In particular, the invention relates to the use of trypsin ZT isoforms in medical devices, pharmaceuticals and cosmetics.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 23, 2021
    Assignee: ENZYMATICA AB
    Inventors: Agusta Gudmundsdottir, Asgeir Asgeirsson, Bjarki Stefansson
  • Patent number: 11154596
    Abstract: Provided herein are methods for use in safe and effective thrombolysis, e.g., in therapy for a potential stroke or acute myocardial infarction (“AMI”) at a maximum arterial patency rate with minimal associated hemorrhagic side effects.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 26, 2021
    Assignee: Thrombolytic Science, LLC
    Inventor: Victor Gurewich
  • Patent number: 11154586
    Abstract: The present disclosure describes use of oxytocin, in combination with one or more other agents as described herein, for use for example in the treatment of certain conditions.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: October 26, 2021
    Assignee: Olive Therapeutics, LLC
    Inventor: E. Quattrocki Knight
  • Patent number: 11147859
    Abstract: The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: October 19, 2021
    Assignee: DIFFUSION PHARMACEUTICALS LLC
    Inventor: John L. Gainer
  • Patent number: 11124752
    Abstract: The present invention provides for methods and at least partially automated devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. Tissue regeneration in humans is extremely limited and constitutes a major challenge to the repair of damaged organ function. Wound treatment is a typical area where tissue regeneration is required. Wounds (lacerations or openings) in mammalian tissue can result in tissue disruption and coagulation of the microvasculature at the wound face.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: September 21, 2021
    Assignee: AVITA MEDICAL LTD
    Inventors: Andrew Perry Quick, David Allen Fencil, William Ford Dolphin
  • Patent number: 11071787
    Abstract: The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 27, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: James C. Cloyd
  • Patent number: 11046818
    Abstract: The present disclosure relates to a dry composition which reconstitutes without mechanical mixing to form a flowable paste having a soft and light consistency suitable for use in haemostasis and wound healing procedures upon addition of an aqueous medium. The disclosure further relates to methods of preparing the dry composition, methods for reconstituting the dry composition and medical use of the composition.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: June 29, 2021
    Assignee: Ferrosan Medical Devices A/S
    Inventors: Kristian Larsen, Flemming Reissig Jensen, Michael Wrang Mortensen
  • Patent number: 11009513
    Abstract: The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: May 18, 2021
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Elena Grimberg, Roberto Meidler, Yonit Tiberman, Nadav Orr, Nadav Ashkenazy
  • Patent number: 10967041
    Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: April 6, 2021
    Assignee: NoNO Inc.
    Inventor: Michael Tymianski
  • Patent number: 10919934
    Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 16, 2021
    Assignee: Emory University
    Inventors: Michael Koval, Barbara Schlingmann
  • Patent number: 10869912
    Abstract: Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 22, 2020
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Assaf Gershonovitch, Rivka Kaufman
  • Patent number: 10738079
    Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 11, 2020
    Assignee: Emory University
    Inventors: Michael Koval, Barbara Schlingmann
  • Patent number: 10675335
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 9, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Patent number: 10624910
    Abstract: The present invention provides an agent for reducing a side effect of an anticancer drug, which comprises a thrombin-like enzyme.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: April 21, 2020
    Assignee: TOBISHI PHARMACEUTICAL CO., LTD.
    Inventors: Hirobumi Senga, Yongling Wan
  • Patent number: 10604749
    Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: March 31, 2020
    Assignee: DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
  • Patent number: 10548984
    Abstract: The invention relates to short RVG derived peptides for use in delivering therapeutic agents across the blood brain barrier and to target cells, for example those cells in the central nervous system. The invention provides method and compositions to treat diseases, such as neurodegenerative diseases, with therapeutic agents associated with targeting peptides.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: February 4, 2020
    Assignee: United Arab Emirates University
    Inventor: Omar M. Ali El-Agnaf
  • Patent number: 10543260
    Abstract: The instant disclosure provides replacement gene tolerizing vectors and methods of using such vectors for treating individuals receiving gene therapy for muscular dystrophy, e.g., Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), etc. Aspects of the methods include administering to the individual, in need thereof, an effective amount of a gene therapy tolerizing vaccine composition that includes a replacement gene tolerizing vector to reduce one or more symptoms of a subject's immune response to gene therapy treatment for muscular dystrophy and/or improve the efficacy of the gene therapy. Compositions and kits for practicing the methods of the disclosure are also provided.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lawrence Steinman, Peggy Pui-Kay Ho
  • Patent number: 10508270
    Abstract: The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin, and the thrombin produced by this method.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 17, 2019
    Assignees: AbSci LLC, Aronora Inc.
    Inventors: Sean McClain, Mark Valasek, Andras Gruber
  • Patent number: 10391152
    Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 27, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Haiyan Jiang, Lei Diao, Shuanglian Li, Paula Cobb
  • Patent number: 10328083
    Abstract: Provided herein is a method of treating a subject believed to have suffered a stroke. This method comprises administering to the subject a therapeutically effective amount of a composition comprising conivaptan or an active derivative, stereoisomer, pro-drug, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: June 25, 2019
    Assignee: University of South Florida
    Inventors: David Andrew Decker, Keith Pennypacker
  • Patent number: 10314894
    Abstract: A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: June 11, 2019
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Qingyu Wu, Shenghan Chen
  • Patent number: 10301612
    Abstract: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 28, 2019
    Assignee: PROTEON THERAPEUTICS, INC.
    Inventors: F. Nicholas Franano, Kimberly Bland, Marco D. Wong, Bee C. Ding
  • Patent number: 10238614
    Abstract: This disclosure relates to the use of EACA (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof. In certain embodiments, subjects with stable chronic thrombocytopenia previously managed with platelet transfusion represent a selected group of patients that benefit from prophylaxis.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 26, 2019
    Assignee: Emory University
    Inventors: Hanna Jean Khoury, Ana Antun
  • Patent number: 10220078
    Abstract: Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 5, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Darrell Carney, Carla Kantara, Stephanie Moya
  • Patent number: 10213379
    Abstract: Pharmaceutical formulations in suppository form, containing thrombolytic agents, which are able to penetrate rectal mucous, for the treatment of acute hemorrhoid diseases and/or diseases of thrombotic origin.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 26, 2019
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECHNOLOGIA
    Inventors: Maria Acelia Marrero Miragaya, Ana Aguilera Barreto, Lisette Gonzalez Chavez, Eduardo Martinez Diaz, Beatriz Torrez Cabrera, Karelia Cosme Diaz, Luciano Francisco Hernandez Marrero, Beatriz Tamargo Santos
  • Patent number: 10174325
    Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 8, 2019
    Assignee: Vitrisa Therapeutics, Inc.
    Inventors: Carl Erickson, Christopher P. Rusconi, Kevin G. McLure
  • Patent number: 10166177
    Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 1, 2019
    Assignee: Silk Therapeutics, Inc.
    Inventors: Gregory H. Altman, Rebecca L. Lacouture, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
  • Patent number: 10159720
    Abstract: Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 25, 2018
    Assignee: Omrix Biopharmaceuticals LTD
    Inventors: Erez Ilan, Assaf Gershonovitch, Rivka Kaufman
  • Patent number: 10143672
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Biosuccess Biotech Co., Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Patent number: 10105447
    Abstract: Modified canine leptin polypeptides and formulations and uses thereof, are provided including polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide, and related compositions and methods useful in treating companion animal obesity and other leptin-related disorders.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 23, 2018
    Assignees: ELANCO US INC., AMBRX, INC.
    Inventors: Michael Bledsoe, Peter Connor Canning, Michael Deguzman, Nick Knudsen, Ianina Valenta
  • Patent number: 10064910
    Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment invoices administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g. by administration of tPA). Administration a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.
    Type: Grant
    Filed: June 23, 2012
    Date of Patent: September 4, 2018
    Assignee: NoNO Inc.
    Inventor: Michael Tymianski
  • Patent number: 10053500
    Abstract: The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: August 21, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Chee Kong Lai, Roddy Kevin Stafford
  • Patent number: 9914918
    Abstract: Factor VII variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 13, 2018
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Paris Margaritis, Giulia Pavani
  • Patent number: 9839646
    Abstract: Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of T-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. For example, the compound that inhibits a plurality of mammalian DASH serine proteases may be t-butylGly-boroPro.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: December 12, 2017
    Assignee: Trustees of Tufts College
    Inventor: William W. Bachovchin
  • Patent number: 9808532
    Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)n-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutatmates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: November 7, 2017
    Assignee: The Regents of the University of California
    Inventors: Roger Tsien, Emilia Olson, Tao Jiang, Quyen Nguyen, Michael Whitney
  • Patent number: 9775888
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: October 3, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9750784
    Abstract: The present invention relates to pharmaceutical preparations and medicaments for intraarticular administration, comprising pepstatin, and to the preparation and use thereof, in particular in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia, particularly preferably in arthrosis.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: September 5, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Ralf Wodopia, Hans Guehring, Sven Lindemann
  • Patent number: 9707269
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 18, 2017
    Assignee: CSL BEHRING GMBH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
  • Patent number: 9649342
    Abstract: Compositions and processes for the effective and efficient regeneration of spinal discs are provided. These compositions contain stem cells, donor cells, and platelet plasma compositions. By using these compositions, there is an increased likelihood of acceptance and proper cell differentiation.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 16, 2017
    Assignee: Laser Spine Institute, LLC
    Inventor: Mark Flood
  • Patent number: 9587233
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 7, 2017
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Patent number: 9579367
    Abstract: The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: February 28, 2017
    Assignee: Canadian Blood Services
    Inventor: Ed Pryzdial
  • Patent number: 9567637
    Abstract: The present invention provides a method of diagnosing a cerebrovascular disease in a human comprising the steps of: (a) measuring a mutation of HTRA1 gene in a test sample from said human; and (b) determining if the mutation of HTRA1 gene in said test sample correlates with a cerebrovascular disease in said human.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: February 14, 2017
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Shoji Tsuji, Osamu Onodera
  • Patent number: 9550722
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 24, 2017
    Assignee: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen